Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Review uri icon

Overview

abstract

  • Entrectinib is a potent small-molecule tyrosine kinase inhibitor that targets oncogenic rearrangements in NTRK, ROS1, and ALK. The consolidated results of 2 Phase I trials demonstrated activity in tyrosine kinase inhibitor-naïve patients along with substantial intracranial activity. In ROS1-rearranged lung cancers, entrectinib results in durable disease control and prolonged progression-free survival. The drug is well tolerated and has a safety profile that includes adverse events mediated by on-target tropomyosin-related kinase A/B/C inhibition.

publication date

  • July 20, 2018

Identity

PubMed Central ID

  • PMC6055893

Scopus Document Identifier

  • 85058463128

Digital Object Identifier (DOI)

  • 10.2147/TCRM.S147381

PubMed ID

  • 30050303

Additional Document Info

volume

  • 14